# A hip can feel better even when the X-ray stays the same

*Relief and X-Ray Change | Hip Regeneration Surprise*

> Hip regeneration Surprise AZ research separates felt relief from X-ray change. Walking, sleep, follow-up, and side effects matter too.

A hip may feel looser during the morning walk, while its X-ray looks unchanged. Both results can be true. Soreness and joint wear aren't the same measure. The word regeneration doesn't show that new tissue has appeared.

## Walking, sleep, and dressing show whether relief changes the day

A small change on a pain score may not affect daily life. Useful relief may mean a longer walk, sounder sleep, or easier socks. Tell the clinician which of those things changed. Saying only that the hip feels better gives less help.

Early relief may fade when normal activity returns. Some hip studies end before they can show how long relief lasts. A claim about lasting relief isn't settled when the study stopped earlier.

A few dated notes can help. Write down the sore task and what made it easier. This doesn't need to become a formal diary. Bring the notes and an old X-ray to the exam.

## An X-ray cannot show how the hip feels during the day

An X-ray shows the bones and space inside the joint. It can't show your sleep, walking, or the effort needed for socks. Some people have wear on an image with little soreness. Other people hurt despite milder wear on X-ray.

Claims about new tissue need proof from a later image. A change on that image still doesn't prove less soreness. Good research checks the image and the person's daily tasks. Strong hip studies haven't shown that a joint shot rebuilds the hip.

After a clinician examines the sore hip, QC Kinetix can discuss joint preservation care, meaning non-surgical choices.

At the visit, ask what change you may feel and when. Also ask about swelling, stiffness, or soreness after the procedure.

## Sources

1. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.
   Gazendam A, et al. — [Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.](https://pubmed.ncbi.nlm.nih.gov/32829298/). *British Journal of Sports Medicine*, 2021. DOI: 10.1136/bjsports-2020-102179.
2. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.
   Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021.
3. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both.
   Jin WS, et al. — [Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39154667/). *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*, 2025. DOI: 10.1016/j.arthro.2024.07.027.
4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.
   Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w.
5. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.
   Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415.
6. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.
   Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181.
7. A randomized controlled study of 111 patients aged 18-65 with hip osteoarthritis compared three weekly ultrasound-guided injections of PRP, hyaluronic acid, or both. PRP had the lowest VAS at every follow-up and beat HA significantly at 6 months (mean VAS 21 vs 44). But the WOMAC advantage present at 2 and 6 months was NO LONGER significant at 12 months, and the combination arm did worse than PRP alone.
   Dallari D, et al. — [Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study.](https://pubmed.ncbi.nlm.nih.gov/26797697/). *The American journal of sports medicine*, 2016. DOI: 10.1177/0363546515620383.
8. A systematic review and meta-analysis of six Level I/II randomized trials (211 PRP and 197 hyaluronic acid patients, mean follow-up ~12 months) found NO significant difference between PRP and hyaluronic acid in WOMAC, VAS or Harris Hip Score improvement for hip osteoarthritis, including in the leukocyte-poor PRP subanalysis.
   Belk JW, et al. — [Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/34785294/). *Arthroscopy*, 2022. DOI: 10.1016/j.arthro.2021.11.005.
9. A meta-analysis of 9 Level-1 trials (671 patients) of adipose stromal vascular fraction and adipose-derived MSC injections for knee OA found SVF superior to saline or hyaluronic acid on pain and function at 3, 6 and 12 months - but INFERIOR to corticosteroid at 3 months, no different at 6, and only comparable or slightly superior at 12. Adipose-derived MSCs beat saline and conservative care but showed no significant difference versus HA. No serious adverse events were attributed to the injections themselves, though complications associated with the LIPOSUCTION step were observed.
   Han JH, et al. — [Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/39914607/). *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*, 2025. DOI: 10.1016/j.arthro.2025.01.050.
10. A Level-1 systematic review of 8 randomized trials (937 patients) of bone marrow aspirate concentrate for knee OA found BMAC improved clinical scores versus baseline from one month, and beat hyaluronic acid on pain at 6 and 12 months with statistical significance - but those differences DID NOT EXCEED the minimal clinically important difference, and against other injections no significant difference appeared at all. Statistically detectable is not the same as noticeable.
   Han JH, et al. — [Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/39640186/). *Orthopaedic journal of sports medicine*, 2024. DOI: 10.1177/23259671241296555.
11. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.
   Hall M, et al. — [Exercise for osteoarthritis of the hip.](https://pubmed.ncbi.nlm.nih.gov/42486497/). *Cochrane Database of Systematic Reviews*, 2026. DOI: 10.1002/14651858.CD007912.pub3.
12. In a placebo-controlled, participant- and assessor-blinded RCT of 102 people with radiographically confirmed hip OA, 12 weeks of active physical therapy (education, manual therapy, home exercise, gait aid) did NOT beat sham ultrasound and inert gel on pain (mean difference 6.9 mm favouring sham, 95% CI -3.9 to 17.7) or function at week 13, and mild adverse effects were more common in the active group (41% vs 14%).
   Bennell KL, et al. — [Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial.](https://pubmed.ncbi.nlm.nih.gov/24846036/). *JAMA*, 2014. DOI: 10.1001/jama.2014.4591.
13. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.
   American Academy of Orthopaedic Surgeons — [Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.](https://www.aaos.org/oahcpg). *AAOS*, 2017.

## An exam can connect the sore movement with its cause

A clinic visit can match your soreness with movement, earlier care, and an X-ray. QC Kinetix in Peoria can discuss non-surgical choices after that exam. Ask which daily task may change and how long relief may last.

Schedule a free consultation: <https://hip.qckaz.com/?src=hipregenerationsurprise.com>

---

Straight answers for a sore hip.

Why a hip gets sore, what may help at home, when to seek care, and which non-surgical choices are offered near Surprise, Arizona.

Plain information about hip soreness, warning signs, simple home steps, and questions for a clinic exam.

This site is written and operated by the owners of the QC Kinetix Phoenix-area clinics, which include the Peoria location nearest to Surprise. We recommend that clinic on this page and we are the people who run it, so read the grades on their own evidence rather than on our say-so — every one of them names the study it came from.

© 2026 Trial by Trial · Surprise, Arizona. Educational content only, and not a substitute for examination, diagnosis or advice from a qualified clinician.